NEW YORK, April 8, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Bristol-Myers Squibb Company (NYSE: BMY), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Illumina Inc. (NASDAQ: ILMN), and West Pharmaceutical Services, Inc. (NYSE: WST). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
--
Biogen Idec Inc. Analyst Notes
On March 31, 2014, Biogen Idec Inc. announced that it will report its Q1 2014 financial results on April 23, 2014, before the market opens. According to the Company, it will also host a live webcast on the same day at 8:00 a.m. ET to discuss the results. The full analyst notes on Biogen Idec Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04082014/BIIB/report.pdf
--
Bristol-Myers Squibb Company Analyst Notes
On April 1, 2014, Bristol-Myers Squibb Company announced that it will report its Q1 2014 financial results on April 29, 2014. The Company informed that its executives will also review the financial information and will address inquiries from investors and analysts during a conference call scheduled on the same day at 9:00 a.m. ET. The full analyst notes on Bristol-Myers Squibb Company are available to download free of charge at:
http://www.AnalystsReview.com/04082014/BMY/report.pdf
--
Regeneron Pharmaceuticals, Inc. Analyst Notes
On April 3, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron) reported that it has entered into collaboration with NASA, Teachers College, Columbia University and the STEM Education Leadership Center of Rye, New York to create the Hudson Valley STEM Teaching Fellowship. George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories, stated, "Regeneron is all about using cutting-edge science to understand biology and develop new drugs. We believe it is important to raise the level of science education in our communities to graduate students who are scientifically literate, as from this soil will spring the scientists of tomorrow. We are pleased to provide fellowships and mentorships to enable this new teacher-training program, which builds on several other science education programs sponsored by Regeneron." The full analyst notes on Regeneron Pharmaceuticals, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04082014/REGN/report.pdf
--
Illumina Inc. Analyst Notes
On April 2, 2014, Illumina Inc. (Illumina) announced the introduction of new products that can be applied directly to the discovery and translation of genomic variation in blood and tissues associated with cancer. According to Illumina, the new product additions include TruSeq® RNA Access Library Prep Kits, TruSight' Myeloid Sequencing Panel, and New BaseSpace® Core Apps. Commenting on the launch, Rick Klausner, M.D. Chief Medical Officer of Illumina, stated, "The latest additions to our product portfolio address the unique needs of oncology researchers. Our product solutions now support library preparation of the low-input, poor-quality archival tissue samples that are so valuable for cancer research. We're accelerating the discovery of cancer-associated variants with simple-to-use data analysis solutions, including software tools that support the creation of genotypic/phenotypic databases. Our goal is to expand the use of NGS beyond basic research, delivering relevant oncological genomic information to clinical researchers where it has the potential to inform improvements in cancer care." The full analyst notes on Illumina Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04082014/ILMN/report.pdf
--
West Pharmaceutical Services, Inc. Analyst Notes
On April 3, 2014, West Pharmaceutical Services, Inc.'s stock went up by 0.46%, closing at $45.01. Over the past five-day trading period, the Company's shares went up by 5.96%, compared to the Dow Jones Industrial Average Index which went up by 1.90% during the same five-day trading period. The full analyst notes on West Pharmaceutical Services, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04082014/GILD/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
